Fig. 7

In vivo tumor inhibition effects of CPT-11-loaded DSPE-PEG₂₀₀₀ targeting EGFR liposome in the SW620 xenograft model. A The tumor volume of nudes treated with CPT-11, CPT-11-Lipo, EGFR-Lipo-CPT-11 and control every 3 days for 24 days; B the tumor mass of nudes treated with four different treatment groups mentioned above (*p < 0.05, **p < 0.01). CPT-11, irinotecan; Lipo-CPT-11, CPT-11 loaded liposome; EGFR-Lipo-CPT-11; CPT-11-loaded DSPE-PEG2000 targeting EGFR liposome